A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen-Specific T Cells (MT-601) Administered to Patients with Relapsed or Refractory Non-Hodgkin Lymphoma (NHL [APOLLO])

Primary Objective

Dose Escalation: To assess safety and tolerability of escalating doses of MT-601. To determine the preliminary recommended phase 2 dose and schedule (RP2DS) Dose Expansion: To assess anti-tumor activity of MT-601 based on 2014 Lugano criteria or other disease specific response criteria

Is This Study For You?

Let's Get Started!

Details
Age
Adult
Locations

CTRC Inpatient
Outpatient CTRC
University of Colorado Hospital

Principal Investigator
Photograph of MANALI KAMDAR

MANALI KAMDAR

Study ID

Protocol Number: 23-0056

More information available at ClinicalTrials.gov: NCT05798897

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers